| Exclusion Criteria: | Acute exacerbations of cystic fibrosis (CF).
Acute or chronic meningitis.
Brain abscess.
Acute or subacute bacterial endocarditis, i.e. ABE or SBE.
Ciprofloxacin as antimicrobial prophylaxis (regardless of the condition being prophylaxed against).
Bone and joint infections, e.g. septic arthritis.
Pts or NB with personal HX of>/=1:Pt w/ blood relatives with/but no personal HX of: arthritis, JRA,RA,SLE,OA, spondylitis, rheumatic fever, psoriasis, inflammatory bowel disease, Behcet's syndrome, chondromalacia, hypermobility.
Have sustained broken bones including small & large bone fractures within </= 90 days prior to course of ciprofloxacin.
Known underlying rheumatological disease, joint problems secondary to trauma or pre-existing conditions known to be associated with arthropathy. Spina Bifida pts not to exceed 20%.
Pts with any pre-treatment baseline musculoskeletal exam abnormalities also are to be excluded from trial participation.
Known risk of experiencing seizures, HX of any convulsive disorders or head injury trauma, currently on anti-seizure meds or within 2 months post-stroke.
Concomitant therapeutic course of systemic antibacterial agent required. Low-dose systemic antibacterial agents for prophylaxis prior to trial entry, OK.
Participation in any industry-sponsored clinical drug study within 1 month prior to this study (exception are pts enrolled in the Cipro pediatric cUTI trial).
Known significant liver impairment (ALAT/ASAT and/or baseline bilirubin > 3xULN).
Known significant renal insufficiency (calculated creatinine clearance of <30 ml/min/1.73 m2).
Pregnant or lactating, sexually active pts using unreliable contraception.
Pts reliant on infant formula for nutrition such that dosing of study medication 6 hrs before or 2 hrs after feeding would not be possible.
|